BNP (B-type Natriuretic Peptide) vs PEG-MGF
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
BNP (B-type Natriuretic Peptide)
BNP is a cardiac neurohormone released primarily by ventricles in response to volume/pressure overload. It's a major biomarker for heart failure and has therapeutic applications as nesiritide.
Full details →PEG-MGF
PEG-MGF (PEGylated Mechano Growth Factor) is a variant of IGF-1 that is produced in response to muscle damage. PEGylation extends its half-life from minutes to several hours, making it practical for use.
Full details →Side-by-Side Comparison
| Aspect | BNP (B-type Natriuretic Peptide) | PEG-MGF |
|---|---|---|
| Dose Range | 25 mcg–100 mcg | 400 mcg–1.2 mg |
| Frequency | 1x daily | Less than daily |
| Cycle Length | 1–4 weeks | 4–6 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Similar to ANP - activates NPR-A receptors to produce vasodilation, natriuresis, and RAAS suppression. Released in response to ventricular wall stress. | Activates muscle satellite cells (stem cells) and promotes their fusion to existing muscle fibers for repair and growth. MGF is produced naturally in response to mechanical stress on muscles. |
| Typical Dosage | Nesiritide (recombinant BNP): 2mcg/kg IV bolus followed by 0.01mcg/kg/min continuous infusion for acute decompensated heart failure. | Research protocols typically use 200-400mcg injected into targeted muscle groups 2-3 times weekly, usually post-workout. |
| Administration | Intravenous administration only. Used in acute care settings for heart failure. BNP levels also used diagnostically. | Intramuscular injection, ideally into muscles trained that day. Best administered post-workout when satellite cell activation is relevant. |
| Side Effects | Hypotension (common and dose-limiting), headache, nausea, and potential renal function worsening in some patients. | Injection site soreness, potential hypoglycemia, and localized swelling. Generally well-tolerated. |
| Best For |
What They Have in Common
BNP (B-type Natriuretic Peptide), PEG-MGF are both commonly used for:
Key Differences
Unique to PEG-MGF:
Which Has Stronger Evidence?
| Goal | BNP (B-type Natriuretic Peptide) | PEG-MGF |
|---|---|---|
| Recovery & Healing | medium | medium |
Key Studies
BNP (B-type Natriuretic Peptide)
- Developing a risk score for B-type natriuretic peptide (BNP) ≥ 100 pg/ml levels: the suita study.
BMC cardiovascular disorders, 2025
- Inhibition of Fap Promotes Cardiac Repair by Stabilizing BNP.
Circulation research, 2023
- Body Composition Measures and N-terminal pro-B-type Natriuretic Peptide (NT-pro-BNP) in US Adults.
Clinical chemistry, 2023
Ready to Learn More?
Looking for trusted sources?